Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA

Waqar Haque, Vivek Verma, Gary D. Lewis, Simon S. Lo, Edward Brian Butler, Bin S. Teh

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Aim: This study evaluated national practice patterns of cT1N0M0 renal cell cancer, with a focus on stereotactic body radiation therapy (SBRT) utilization. Methods: The National Cancer Database was queried (2004-2013) for patients with newly-diagnosed cT1a/bN0M0 renal cell cancer that received definitive treatment. Temporal trends in utilization were tabulated. Results: Altogether, 138,495 patients met inclusion criteria; 13,725 (9.9%) patients received ablative therapy, 57,924 (41.8%) partial nephrectomy, 67,168 (48.5%) radical nephrectomy and 308 (0.2%) external beam radiation therapy (EBRT). The proportion of EBRT that was SBRT increased substantially from 25% in 2004 to 95.4% in 2013, with a sharp inflection point from 2005 to 2006. Conclusion: SBRT utilization has sharply risen over time; in most recent years, the vast majority of EBRT is delivered in the form of SBRT.

Original languageEnglish (US)
Pages (from-to)819-827
Number of pages9
JournalFuture Oncology
Volume14
Issue number9
DOIs
StatePublished - Apr 2018

Keywords

  • kidney cancer
  • nephrectomy
  • radiation therapy
  • renal cell carcinoma
  • stereotactic ablative radiation therapy
  • stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA'. Together they form a unique fingerprint.

Cite this